Target Solvent
Bacteriostatic Water USP (0.9% Benzyl Alcohol)
Clear royal blue aqueous solution. Precipitation or fading indicates pH imbalance or copper chelate dissociation.
Validated Laboratory Standard
Revision 1 · Lyophilized Solid Powder
Copper Tripeptide Transcriptional Modulator & Matrix Reconstitution Standard. Formulated for in-vitro research and laboratory analytical validation.
Copper Tripeptide Transcriptional Modulator & Matrix Reconstitution Standard. Formulated for in-vitro research and laboratory analytical validation.
What it is: GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper) is a naturally occurring human tripeptide chelated with a copper(II) ion, present in human plasma, saliva, and urine, where its levels decline significantly with age.
How it works: GHK-Cu regulates over 4,000 human genes, shifting gene expression toward youthful cellular repair. It stimulates both collagen and elastin synthesis, enhances fibroblast production, activates nerve outgrowth, and acts as a potent antioxidant by quenching free radicals and toxic lipid peroxidation products.
Why researchers study it: Studied extensively for skin rejuvenation, wrinkle reduction, wound repair, anti-aging, hair follicle stimulation, and reversing tissue fibrosis in organs and joints.
Analysis of Glycyl-L-Histidyl-L-Lysine Cu(II) Chelation, Transcriptional Reprogramming of Over 4,000 Genes, Decorin Induction, and Wound Remodeling.
GHK-Cu (molecular formula C14H22CuN6O4, molecular weight 401.91 Da) exists as a stoichiometric 1:1 coordination complex between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The copper atom is tetracoordinated in a square-planar geometry by: (1) the amino-terminal nitrogen of glycine; (2) the deprotonated amide nitrogen of the Gly-His peptide bond; (3) the deprotonated amide nitrogen of the His-Lys peptide bond; and (4) the imidazole nitrogen atom (N-pi) of the histidine side-chain.
This square-planar coordination creates a thermodynamic stability constant of log K = 16.4, which matches the copper affinity of human serum albumin (log K = 16.2). As a result, GHK can readily exchange Cu(II) with albumin and transport it safely through the circulation without releasing free, unchelated copper ions that could catalyze toxic hydroxyl radical generation via Fenton-type reactions.
Spectrophotometric analysis of the aqueous complex reveals a characteristic d-d transition absorption maximum at 605 nm, imparting a vibrant royal blue color that serves as a direct analytical indicator of complete 1:1 copper stoichiometric chelation.
Using the Broad Institute's Connectivity Map (CMap) genomic database, Pickart and Margolina (Int J Mol Sci 2018) revealed that GHK-Cu significantly modulates the expression of 4,192 human genes (2,014 upregulated, 2,178 downregulated) at physiological concentrations (10^-9 to 10^-8 M).
Crucially, GHK shifts the genomic expression pattern of aged or senescent human fibroblasts back toward that of youthful, undamaged cells. Genes involved in DNA excision repair (such as OGG1, ERCC1, and XPA) are significantly upregulated, enhancing the cell's capacity to repair oxidative DNA damage. Concurrently, antioxidant defense genes including Cu/Zn superoxide dismutase (SOD1), catalase, and glutathione S-transferase are activated.
In contrast, pro-inflammatory and pro-fibrotic signaling cascades are suppressed: GHK-Cu downregulates transforming growth factor-beta (TGF-beta1), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6), thereby preventing unregulated extracellular scar deposition and chronic sterile tissue inflammation.
In dermal fibroblast culture models, GHK-Cu stimulates the biosynthesis of pro-collagen Type I and pro-collagen Type III by approximately 70% compared to untreated controls. In comparative head-to-head in vitro studies, GHK-Cu stimulated collagen synthesis more potently than both all-trans retinoic acid (retinoids) and ascorbic acid (vitamin C) without inducing cytotoxicity, erythema, or barrier disruption.
Equally important is GHK-Cu's capacity to induce decorin synthesis. Decorin is a small leucine-rich proteoglycan that binds to specific domains on collagen fibrils, regulating fibrillogenesis and ensuring uniform, parallel fiber diameter. By elevating decorin expression, GHK-Cu prevents the chaotic, cross-linked, disorganized collagen bundles characteristic of keloid and hypertrophic scar tissue, promoting functional, pliable tissue architecture.
GHK-Cu also restores the balance between extracellular matrix synthesis and degradation by upregulating matrix metalloproteinases (MMP-1 and MMP-2) to clear damaged, glycation-crosslinked collagen, while simultaneously elevating tissue inhibitor of metalloproteinases 1 (TIMP-1) to protect newly synthesized structural proteins from excessive proteolytic digestion.
Pure GHK-Cu is supplied as an intensely blue, crystalline lyophilized powder. The chemical composition requires precise 1:1 molarity between GHK free base and Cu2+; excess unchelated copper produces a green tint, while copper deficiency results in a pale blue or white color.
Reconstitution protocol: for a standard 50.0 mg vial, the addition of 5.0 mL of Bacteriostatic Water USP (0.9% benzyl alcohol) or Sterile Water for Injection yields a stock concentration of 10.0 mg/mL (10,000 mcg/mL). For micro-dosing models, adding 10.0 mL diluent yields a 5.0 mg/mL solution.
Syringe calibration on a standard U-100 syringe (100 units = 1.0 mL; 1 unit = 0.01 mL = 100 mcg GHK-Cu at 10 mg/mL): a research dose of 1,000 mcg (1.0 mg) corresponds to 10 units (0.10 mL); a 2,000 mcg (2.0 mg) dose corresponds to 20 units (0.20 mL). Reconstitution is virtually instantaneous upon solvent contact, forming an optically transparent, deep blue solution with pH between 6.0 and 7.2.
Storage parameters: Lyophilized solid vials remain stable at -20°C for up to 36 months, or 2°C–8°C for 24 months. Reconstituted solutions containing 0.9% benzyl alcohol must be stored refrigerated at 2°C–8°C away from strong oxidizing agents and light, remaining chemically stable for 28 days.
GHK-Cu possesses an extensive human and animal safety history spanning over 40 years of dermatological and wound care research. Because GHK is an endogenous component of human plasma, saliva, and urine, it exhibits virtually no systemic toxicity at physiological or pharmacological research concentrations.
In human patch testing and repeat insult patch tests (RIPT), topical GHK-Cu formulations up to 3% concentration produced no primary dermal irritation, allergic contact sensitization, or phototoxicity. Systemic LD50 in animal studies exceeds 1,000 mg/kg parenterally.
Furthermore, extensive in vitro Ames mutagenicity testing and chromosomal aberration assays have verified that GHK-Cu is non-mutagenic, non-clastogenic, and non-carcinogenic. Because bound copper is firmly sequestered within the square-planar chelate, systemic administration does not perturb systemic copper homeostasis or elevate free plasma copper levels.
Target Solvent
Bacteriostatic Water USP (0.9% Benzyl Alcohol)
Clear royal blue aqueous solution. Precipitation or fading indicates pH imbalance or copper chelate dissociation.
Diluent Ratio
2.5 mL per 50 mg (20 mg/mL)
Add 2.5 mL Bacteriostatic Water slowly. Solution immediately turns characteristic deep royal blue. Swirl gently for 30 seconds. Do not sonicate, freeze-thaw repeatedly, or vortex.
Lyophilized Storage
-20°C in dark desiccator (24 months)
Desiccated and protected from thermal spikes
Liquid Stability
2°C–8°C refrigerated; use within 28 days. Keep strictly shielded from direct light
Refrigerated and light-protected
Pharmacokinetics / Half-Life
~1–2 Hours (Rapid systemic copper exchange; tissue extracellular retention ~48–72h)
Typical protocol duration: 30 to 60 Days continuous trial series; Washout: 30 Days between cycles to allow physiological copper clearance
| Standard Compound Mass | 50 mg active per vial |
| Recommended Diluent | Bacteriostatic Water USP (0.9% Benzyl Alcohol) |
| Diluent Volume Added | 2.5 mL |
| Resulting Concentration | 20.0 mg/mL |
| Syringe Volumetric Scale | U-100 Syringe (100 units = 1.0 mL | 1 unit = 200.0 mcg (0.01 mL)) |
| Handling Rule | Clear royal blue aqueous solution. Precipitation or fading indicates pH imbalance or copper chelate dissociation. |
Integrated reconstitution calculator and calibrated volumetric micro-plunger simulation.
Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.
| Escalation Stage & Phase | Target Dose | U-100 Mark (50mg / 2.5mL) | Cadence | Syringe Sync |
|---|---|---|---|---|
| In-Vitro Assay Titration Schedule (Days 1–7) | 1 mg | 5.0 Units(0.05 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Days 8–30) | 2 mg | 10.0 Units(0.10 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Days 31–60) | 0 mcg | 0.0 Units(0.00 mL) | 1x Daily |
| Research Dose | Volume (mL) | U-100 Syringe Graduation Mark |
|---|---|---|
| 500 mcg (Micro Calibration) | 0.025 mL | 2.5 Units 2.5 units (0.025 mL) on U-100 syringe |
| 1.00 mg (Standard Target) | 0.050 mL | 5 Units 5.0 units (0.05 mL) on U-100 syringe |
| 2.00 mg (High Output Target) | 0.10 mL | 10 Units 10.0 units (0.10 mL) on U-100 syringe |
| 3.00 mg (Ceiling Protocol) | 0.15 mL | 15 Units 15.0 units (0.15 mL) on U-100 syringe |
| Research Dose | Calibrated Volume | U-100 Syringe Units | Graduation Description |
|---|---|---|---|
| 500 mcg (Micro Calibration) | 0.025 mL (25 µL) | 2.5 Units | 2.5 units (0.025 mL) on U-100 syringe |
| 1.00 mg (Standard Target) | 0.05 mL (50 µL) | 5 Units | 5.0 units (0.05 mL) on U-100 syringe |
| 2.00 mg (High Output Target) | 0.1 mL (100 µL) | 10 Units | 10.0 units (0.10 mL) on U-100 syringe |
| 3.00 mg (Ceiling Protocol) | 0.15 mL (150 µL) | 15 Units | 15.0 units (0.15 mL) on U-100 syringe |
ISO 8537 Sterile Insulin Syringe Standard · Optical Meniscus Resolution & Volumetric Parallax Engineering
Detachable needles leave significant fluid trapped in the plastic hub collar. In peptide protocols, this causes substantial loss of active ingredient per administration.
| Barrel Capacity | Graduation Interval | Volume per Tick | Hub Dead-Space | Needle Spec | Suitability for 3 Units |
|---|---|---|---|---|---|
| 0.3 mL (30 Units)BEST FIT | 0.5 Unit | 5 µL (0.005 mL) | < 0.4 µL | 31G × 5/16" (8mm) Integrated Ultra-Fine | ✓ Accommodates 3 units |
| 0.5 mL (50 Units) | 1 Unit | 10 µL (0.010 mL) | < 0.8 µL | 30G–31G × 5/16" (8mm) Integrated | ✓ Accommodates 3 units |
| 1 mL (100 Units) | 2 Unit | 20 µL (0.020 mL) | < 2.1 µL | 29G–30G × 1/2" (12.7mm) Integrated | ✓ Accommodates 3 units |
Viewing the syringe from an angle introduces a 1.0–2.5 unit parallax error. Always raise the barrel to direct eye level against a high-contrast white background. Align the front edge of the top black plunger seal ring with the target line.
Standard 5/16" (8mm) laboratory dispensing needles are calibrated for direct 90° fluid transfer into target analytical matrix vials. If utilizing 1/2" (12.7mm) cannulas in deep laboratory vessels, introduce at a 45° angle to avoid contact with vessel sidewalls.
Stoichiometric supply planning, sequential reconstitution cadence, and itemized consumables BOM for GHK-Cu.
Do NOT reconstitute all 2 vials simultaneously. Reconstitute one vial at a time as the active protocol requires. Once reconstituted with Bacteriostatic Water USP, a vial maintains stability for 28 days at +2°C to +8°C. Remaining unopened vials should be preserved in solid lyophilized cake form at -20°C to prevent hydrolysis and oxidation.
| Week | Study / Assay Phase | Weekly Target Dose | Syringe Draw (U-100) | Active Vial # | Cumulative Active Mass |
|---|---|---|---|---|---|
| Week 1 | Phase 3: Copper Homeostasis Washout (Days 31–60) | 1.0 mg(7x/wk) | 5 Units(0.05 mL) | Vial #1(43mg rem) | 7.0 mg / 84.0 mg |
| Week 2 | Phase 3: Copper Homeostasis Washout (Days 31–60) | 1.0 mg(7x/wk) | 5 Units(0.05 mL) | Vial #1(36mg rem) | 14.0 mg / 84.0 mg |
| Week 3 | Phase 3: Copper Homeostasis Washout (Days 31–60) | 1.0 mg(7x/wk) | 5 Units(0.05 mL) | Vial #1(29mg rem) | 21.0 mg / 84.0 mg |
| Week 4 | Phase 3: Copper Homeostasis Washout (Days 31–60) | 1.0 mg(7x/wk) | 5 Units(0.05 mL) | Vial #1(22mg rem) | 28.0 mg / 84.0 mg |
| Week 5 | Phase 3: Copper Homeostasis Washout (Days 31–60) | 1.0 mg(7x/wk) | 5 Units(0.05 mL) | Vial #1(15mg rem) | 35.0 mg / 84.0 mg |
| Week 6 | Phase 3: Copper Homeostasis Washout (Days 31–60) | 1.0 mg(7x/wk) | 5 Units(0.05 mL) | Vial #1(8mg rem) | 42.0 mg / 84.0 mg |
| Week 7 | Phase 3: Copper Homeostasis Washout (Days 31–60) | 1.0 mg(7x/wk) | 5 Units(0.05 mL) | Vial #1(1mg rem) | 49.0 mg / 84.0 mg |
| Week 8 | Phase 3: Copper Homeostasis Washout (Days 31–60) | 1.0 mg(7x/wk) | 5 Units(0.05 mL) | Vial #2(43mg rem) | 56.0 mg / 84.0 mg |
| Week 9 | Phase 3: Copper Homeostasis Washout (Days 31–60) | 1.0 mg(7x/wk) | 5 Units(0.05 mL) | Vial #2(36mg rem) | 63.0 mg / 84.0 mg |
| Week 10 | Phase 3: Copper Homeostasis Washout (Days 31–60) | 1.0 mg(7x/wk) | 5 Units(0.05 mL) | Vial #2(29mg rem) | 70.0 mg / 84.0 mg |
| Week 11 | Phase 3: Copper Homeostasis Washout (Days 31–60) | 1.0 mg(7x/wk) | 5 Units(0.05 mL) | Vial #2(22mg rem) | 77.0 mg / 84.0 mg |
| Week 12 | Phase 3: Copper Homeostasis Washout (Days 31–60) | 1.0 mg(7x/wk) | 5 Units(0.05 mL) | Vial #2(15mg rem) | 84.0 mg / 84.0 mg |
Study duration: 30 to 60 Days continuous trial series · Washout: 30 Days between cycles to allow physiological copper clearance
| Period / Phase | Target Amount | Frequency | Notes & Calibration |
|---|---|---|---|
| Days 1–7Starting Baseline | 1 mg | 1x Daily (SubQ) | Phase 1: Micro-Dose Initiation: Baseline tissue tolerance, fibroblast activation & initial SOD1 upregulation (5.0 units (0.05 mL) on U-100 syringe at 20.0 mg/mL concentration) |
| Days 8–30 | 2 mg | 1x Daily (SubQ) | Phase 2: Full Regenerative Block: Peak decorin expression, collagen I/III bundle fibrillogenesis, and anti-inflammatory cytokine modulation (10.0 units (0.10 mL) on U-100 syringe) |
| Days 31–60 | Observation Period | Zero dosing | Phase 3: Copper Homeostasis Washout: Physiological copper clearance and observation of persistent collagen remodeling (30-day rest period prevents copper accumulation in hepatic assays) |
4-phase stability timeline, RP-HPLC degradation benchmarks, and storage SOPs for GHK-Cu
Operating Window: +2°C to +8°C (36°F to 46°F)
Active working solution dissolved in Bacteriostatic Water USP (0.9% Benzyl Alcohol).
| Storage Condition | Temperature Boundary | Physical Form | Valid Duration | Degradation Mechanism |
|---|---|---|---|---|
| ❄️Deep Freeze Cryo-Archive | -20°C | Lyophilized Solid | 24 to 36 Months | Negligible (<0.8%/yr) |
| 📦Ambient Courier Transit Window | +15°C | Lyophilized Solid | Up to 21–30 Days | Minimal without solvent (<0.5%) |
| 💧Reconstituted Refrigerated Storage (2°C–8°C) | +2°C | Reconstituted Solution | 28 to 35 Days | Gradual deamidation >28 days |
| 🚫Critical Degradation Thresholds | >37°C | Degradation Hazard | Immediate Degradation Hazard | Rapid peptide cleavage & aggregation |
Add 2.5 mL Bacteriostatic Water slowly. Solution immediately turns characteristic deep royal blue. Swirl gently for 30 seconds. Do not sonicate, freeze-thaw repeatedly, or vortex.
GHK-Cu displays an estimated half-life of ~1–2 Hours (Rapid systemic copper exchange; tissue extracellular retention ~48–72h). Typical study protocols run for 30 to 60 Days continuous trial series followed by a washout period of 30 Days between cycles to allow physiological copper clearance.
High-purity lyophilized laboratory reference formulation with certified Certificate of Analysis (COA).
Standard Lyophilized Monograph
Copper Tripeptide Transcriptional Modulator & Matrix Reconstitution Standard. Formulated for in-vitro research and laboratory analytical validation.
Store desiccated at -20°C upon receipt. Reconstitute strictly in a certified laminar airflow hood utilizing sterile disposable instruments. Avoid direct exposure to UV or fluorescent radiation.
| Net Active Mass | Target Solvent | Diluent Volume | Resulting Concentration | Syringe Graduation Scale |
|---|---|---|---|---|
| 50 mg Lyophilized Cake | Bacteriostatic Water USP (0.9% Benzyl Alcohol) | 2.5 mL | 20.00 mg/mL | 1 Unit = 200.0 mcg (0.01 mL) |
Swab vial septum with sterile 70% IPA pad. Inspect cake for vacuum seal integrity.
Introduce 2.5 mL solvent slowly down inner glass wall. Never spray directly on cake.
Swirl gently in horizontal circles until fully dissolved. Never shake or invert aggressively.
Rest at +2°C to +8°C for 10 minutes until solution is crystal clear before drawing.
| Phase | Target Active Dose | U-100 Syringe Graduation | Cadence & Pharmacological Purpose |
|---|---|---|---|
| Days 1–7 (Priming) | 1.0 mg | 5.0 Units (0.050 mL) | Initial receptor priming; evaluate baseline physiological tolerance. |
| Weeks 2–4 (Saturation) | 1.5 mg | 7.5 Units (0.075 mL) | Target assay maintenance; peak neurotrophic / metabolic response. |
| Weeks 5–6 (Taper & Washout) | 1.0 mg | 5.0 Units (0.050 mL) | Receptor consolidation prior to mandatory 4-week washout cycle. |
RP-HPLC / LC-MS In-Vitro Assay
Purity Spec: ≥ 98.0% Area
Research Use Only (RUO)
NOT EVALUATED OR APPROVED BY FDA